6. Drug resistance of M. Tuberculosis in patients with rifampicin-resistant xpert MTB/RIF treated with a short-term regimen
Main Article Content
Abstract
Over the past two decades, the emergence of multidrug-resistant tuberculosis has significantly complicated global efforts to control the tuberculosis epidemic. This study aims to describe the antibiotic resistance profiles of Mycobacterium tuberculosis in Vietnamese patients with Rifampicin resistance by Xpert MTB/RIF. We conducted a descriptive, retrospective study on 752 tuberculosis patients with Rifampicin resistance by Xpert MTB/RIF who received a short-course treatment at 35 medical facilities as part of the Resistant TB Management Program in 7 provinces in Vietnam. Among them, 118 cases with isolated M. tuberculosis strains and had antibiotic resistance profiles, the rate of M. tuberculosis resistant to each drug of second-line anti-tuberculosis antibiotic is Moxifloxacin (6.96%); Amikacin (3.39%); Ofloxacin/Levofloxacin (3.51%); Kanamycin (3.39%); Capreomycin (3.39%). Ethionamide, Bedaquiline, and Delamanid were not resistant. Given the high rate of drug-resistant M. tuberculosis and the high burden of tuberculosis in Vietnam, it is important to collect the susceptibility data for key second line drugs to monitor the drug resistance trend and individualize the treatment regimen for those who have resistance to first-line anti-tuberculosis.
Article Details
Keywords
Rifampicin resistant tuberculosis, multidrug-resistant tuberculosis, antibiogram, short-course regimen
References
2. WHO. Companion handbook to the WHO guidelines for the programmatic management of drug-resistant tuberculosis [Internet]. Geneva, Switzerland;. 2015; doi:https://www.who.int/publications/i/item/9789241548809.
3. Gandhi NR NP, Dheda K, Schaaf HS, Zignol M, Van Soolingen D, et al. Multidrug-resistant and extensively drug-resistant tuberculosis: a threat to global control of tuberculosis. Lancet Infect Dis. 2010; 375: 1830-43. doi:doi:10.1016/S01406736(10)60410-2.
4. World Health Organization. Global Tuberculosis Report 2020;doi:https://www.who.int/publications/i/item/9789240013131.
5. World Health Organization. Global Tuberculosis Report 2022;doi:https://www.who.int/teams/global-tuberculosis-programme/tb-reports/global-tuberculosis-report-2022.
6. Bộ Y Tế. Cập nhật hướng dẫn điều trị bệnh Lao kháng thuốc Ban hành kèm theo Quyết định số 2760/QĐ-BYT ngày 03/6/2021 của Bộ trưởng Bộ Y tế. 2021;
7. Organization. WH. Haemoglobin concentrations for the diagnosis of anaemia and assessment of severity. Published online. 2011; doi:https://www.who.int/publications/i/item/WHO-NMH-NHD-MNM-11.1.
8. Bộ y tế. Hướng dẫn quy trình thực hành chuẩn xét nghiệm vi khuẩn lao. Nhà xuất bản y học.; 2014.
9. Nguyễn Hữu Thành PT, Trần Ngọc Dung, và cs. Tình hình lao đa kháng và kết quả điều trị trong 3 năm 2018-2020 tại tỉnh Đồng Tháp. Tạp chí Y học Việt Nam. 2023; Số 1 Tháng 10.
10. Suárez-García I, Rodríguez-Blanco A, Vidal-Pérez JL, et al. Risk factors for multidrug-resistant tuberculosis in a tuberculosis unit in Madrid, Spain. European Journal of Clinical Microbiology & Infectious Diseases. 2009/04/01 2009; 28(4): 325-330. doi:10.1007/s10096-008-0627-y.
11. Aboubacar Sidiki Magassouba MD, Younoussa Sylla, et al. Anaemia and associated factors in multidrug-resistant tuberculosis patients at initiation of treatment in the Republic of Guinea. African Journal of Medical and Health Sciences. 2022; 22(4),: 28-34. doi:10.5897/AJMHS2021.0199.
12. Organization WH. WHO treatment guidelines for drug-resistant tuberculosis: 2022 update [Internet]. 2022; doi:https://www.who.int/publications/i/item/9789240063129.
13. Emily A. Kendall TC, Carole D. Mitnick, David W. Dowdy,. Second line drug susceptibility testing to inform the treatment of rifampin-resistant tuberculosis: a quantitative perspective. International Journal of Infectious Diseases. 2017; 56: 185-189. doi:https://doi.org/10.1016/j.ijid.2016.12.010.
14. A.S. Pym AHD, S.-J. Tang, F. Conradie, M. Danilovits, C. Chuchottaworn, et al. Bedaquiline in the treatment of multidrug- and extensively drug-resistant tuberculosis. Eur Respir J. 2016; 47: 564-574.
15. M.L. Bastos HH, K. Weyer, L. Garcia-Garcia, V. Leimane, C.C. Leung, et al. Treatment outcomes of patients with multidrug-resistant and extensively drug-resistant tuberculosis according to drug susceptibility testing to first- and second-line drugs: an individual patient data meta-analysis. Clin Infect Dis. 2014; 59: 1364-1374.
16. C.M. Yuen EVK, T. Tupasi, J.C. Caoili, M.V.D. Walt, C. Kvasnovsky, et al. Association between Regimen Composition and Treatment Response in Patients with Multidrug-Resistant Tuberculosis: A Prospective Cohort Study. PLOS Med. 2015; 12: e1001932.
17. Y. Zhao SX, L. Wang, D.P. Chin, S. Wang, G. Jiang, et al. National survey of drug-resistant tuberculosis in China. N Engl J Med. 2012; 366: 2161-2170.
18. H.M. Said MMK, N.A. Ismail, M. Mphahlele, K. Baba, S.V. Omar, et al. Molecular characterization and second-line antituberculosis drug resistance patterns of multidrug-resistant Mycobacterium tuberculosis isolates from the northern region of South Africa. J Clin Microbiol. 2012;50:2857-2862.